NEW YORK, Sept.

DOYLESTOWN, Pennsylvania and OXFORD, England, May 9 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen's shareholders at a special meeting on 8 May.

Cytogen Corporation (NASDAQ: CYTO) today reported the publication of data from a large cohort study demonstrating the value of PROSTASCINT® (capromab pendetide) in predicting outcomes for patients with prostate cancer.

Cytogen Corporation (NASDAQ: CYTO), announced toda

Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET® (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma.